Dr. Cui has advised the following companies, among others, in the life sciences industry in the following transactions and matters, among others:
- ACROBiosystems Inc.: various licensing, collaboration, sales, distribution, consulting and investment transactions, and IP matters;*
- A publicly traded, global, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies: various collaboration, licensing, and services transactions, and employee IP matters;*
- A biotechnology company that leverages revolutionary drug targets to develop and commercialize transformational therapies in autoimmune diseases, cancers and transplantations: various services, manufacturing, and consulting agreements;*
- A Shanghai-based biopharma company developing next generation anti-cancer therapies: various licensing and co-development transactions, and IP due diligence matters;*
- A clinical stage biopharmaceutical company with the goal of curing cancer by developing novel T-cell therapies that harness the evolutionary power of the immune system: various licensing, collaboration, and clinical services transactions, and China IP, JV and regulatory matters;*
- Evive Biotechnology (Shanghai) Ltd.: various licensing and collaboration transactions, including with the Memorial Sloan-Kettering Cancer Center, and patent applications;*
- GenScript Biotech Corporation and its clinical-stage oncology biotech subsidiary, Legend Biotech Corporation:
- licensing transactions, including with Amgen and Noile-Immune Biotech, Inc., respectively;*
- technology services transactions;*
- strategic collaborations, including with REMD Biotherapeutics Inc.;*
- various strategic partnership transactions;*
- acquisition of CustomArray, Inc.;* and
- Chinese IP law and compliance matters;*
- HebeCell Corp: various licensing and collaboration transactions;*
- Helio Health Inc.: various licensing transactions, including with universities, and patent applications;*
- Livzon Pharmaceutical Group Inc.:
- $33 million Series B financing of Elicio Therapeutics;*
- $47 million Series B financing of Carisma Therapeutics;* and
- U.S. regulatory advice;*
- Qilu Pharmaceutical Co., Ltd.: various collaboration and licensing transactions;*
- T-Cure Bioscience, Inc.: various licensing and clinical research transactions with biopharma companies and universities, including the license agreement with Immunotech Biopharm Ltd;*
- A global leader of 3D printing pharmaceuticals: various collaboration and services transactions, and employee and consultant IP matters;*
- Vazyme Biotech Co., Ltd: IP dispute and product distribution matters;* and
- Warburg Pincus Asia LLC:
- freedom-to-operate and other China IP due diligence matters;*
- ￥1.2 billion Series B financing of Haihe Pharmaceutical;* and
- $123 million Series D financing of Abbisko Therapeutics.*
*Denotes experience prior to joining Goodwin.
Prior to joining Goodwin, Dr. Cui was an associate in the IP and Technology Transactions Groups of Morrison & Foerster LLP (“MoFo”), where he was a key member of the firm’s China Life Sciences practice. During his four-year residency in the firm’s Hong Kong office, he managed, in addition to cross-border licensing and investment transactions, patent dispute matters in China on behalf of MoFo’s U.S. clients, and gained extensive experience in IP dispute resolution in China. During his subsequent five-year residency in MoFo’s San Francisco office, he continued to represent clients in both China and the U.S. in their cross-border technology transactions and investments, and played a leading role in those transactions in the life sciences industry.
While working in MoFo’s Hong Kong office, Dr. Cui was an adjunct faculty member at The Chinese University of Hong Kong (CUHK). During his three-year tenure at CUHK Faculty of Law, he taught the Principles of Intellectual Property course, and established CUHK’s Chinese IP Law course.
Prior to and while attending law school, Dr. Cui worked as a U.S. patent agent in the Boston and New York offices of Ropes & Gray LLP, where he was a member of the Fish & Neave IP Group.As a graduate student at Harvard, Dr. Cui conceived, established, and maintained a major long-term collaborative project among Harvard Medical School, the University of California, San Diego, and the Chinese Academy of Sciences. His identification of a viral microRNA was featured in the “Spotlight” section of Journal of Virology as an article of significant interest selected by the editors.
在上法学院之前和期间，崔博士作为Fish & Neave知识产权组的成员在瑞格律师事务所的波士顿和纽约办事处担任美国专利代理人。作为哈佛大学的研究生，他构思、建立并维系了一项由哈佛医学院、加州大学圣地亚哥分校和中国科学院共同参与的重要长期合作项目。他的关于病毒微小RNA 的突破性发现发表在《病毒学学报》（Journal of Virology）的“焦点”（Spotlight）专栏，并被编辑特选为极具影响力的文章。
Dr. Cui is a member of American Bar Association, New York State Bar Association, California Lawyers Association, Bar Association of San Francisco, and San Francisco Bay Area Intellectual Property Inn of Court.Dr. Cui is a frequent guest lecturer and panelist at top universities and law schools in the United States and in China on U.S. patent law, cross-border technology licensing, and IP protection in the life sciences industry.